Back to Search
Start Over
Safety of sunitinib in patients with renal cell carcinoma following nephrectomy.
- Source :
-
Expert opinion on drug safety [Expert Opin Drug Saf] 2020 Jul; Vol. 19 (7), pp. 799-806. Date of Electronic Publication: 2020 Jun 10. - Publication Year :
- 2020
-
Abstract
- Introduction: The safety profile characteristics of sunitinib were evaluated in patients who underwent nephrectomy for kidney cancer.<br />Areas Covered: In this literature review, safety data were evaluated from phase III trials investigating sunitinib following nephrectomy, either in the more recent adjuvant setting after nephrectomy or in the metastatic setting, with a focus on new data from the CARMENA and SURTIME trials. In particular, the aim was to determine the specificity of toxicity in the adjuvant setting.<br />Expert Opinion: In the adjuvant setting, even if the toxicity profile of sunitinib does not differ significantly from that in the metastatic setting, the importance of the dose intensity and, thus, exposure has been emphasized. Consequently, as described mainly in the metastatic setting, management of the adverse effects of sunitinib remains critical.
- Subjects :
- Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Carcinoma, Renal Cell pathology
Chemotherapy, Adjuvant
Humans
Kidney Neoplasms pathology
Neoplasm Metastasis
Nephrectomy
Sunitinib adverse effects
Carcinoma, Renal Cell therapy
Kidney Neoplasms therapy
Sunitinib administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1744-764X
- Volume :
- 19
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Expert opinion on drug safety
- Publication Type :
- Academic Journal
- Accession number :
- 32521179
- Full Text :
- https://doi.org/10.1080/14740338.2020.1774551